Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A pilot phase I/II study was conducted as a single-institute trial for evaluation of the feasibility and efficacy of a new salvage chemotherapy, CHASE, for patients with refractory or relapsed lymphoma. The CHASE regimen, consisting of cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone, was administered every 3 weeks in a maximum of 5 courses. A total of 16 patients were eligible and registered for this study. Myelosuppression was the major toxicity. Although grade 4 leukopenia and grade 3 thrombocytopenia were identified in 15 and 16 patients, respectively, duration of the nadir was brief (median, 3 days). Nonhematological grade 4 toxicity was not observed, and transient elevations of bilirubin and grade 3 aspartate aminotransferase/alanine aminotransferase (AST/ALT) were observed in 2 and 3 courses, respectively, in a total of 57 courses. Complete and partial response rates were 71.4% (10/14) and 7.1% (1/14), respectively. The median percentage of maximal CD34+ cells was 6.1% on day 15, and a median number of 1.88 X 106 CD34+ cells/kg per apheresis were obtained. Thirteen patients received high-dose chemoradiotherapy followed by autologous peripheral blood stem cell transplantation. With a median follow-up time of 36 months from the start of CHASE, the overall survival rate for the 16 patients was 66.6%. These results indicated that CHASE is a safe and effective salvage regimen for malignant lymphoma, has sufficient mobilizing effect on peripheral blood stem cells, and warrants further phase II study.
- Devita VT Jr, Serpick AA, Carbone PP. Combination chemo- therapy in the treatment of advanced Hodgkin’s disease.Ann Intern Med. 1970;73:881–895.
- Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease.J Clin Oncol. 1986;4:1295–1306.
- Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.Cancer. 1975;36:252–259. CrossRef
- Bonadonna G, Valagussa P, Santoro A. Alternating non-cross- resistant combination chemotherapy or MOPP in stage IV Hodg- kin’s disease: a report of 8-year results.Ann Intern Med. 1986;104: 739–746.
- Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alter- nating with ABVD.N Engl J Med. 1992;327:1478–1484.
- Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.Ann Intern Med. 1985;102:596–602.
- Coiffier B, Bryon PA, Berger F, et al. Intensive and sequential com- bination chemotherapy for aggressive malignant lymphomas (pro- tocol LNH-80).J Clin Oncol. 1986;4:147–153.
- Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of Pro- MACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trialJ Clin Oncol. 1991;9:25–38.
- Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.N Engl J Med. 1993;328: 1002–1006. CrossRef
- Velasquez W, Fuller LM, Oh KK et al. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas.Cancer. 1984;53:1478–1483. CrossRef
- DeVita VT Jr. Hodgkin’s disease: conference summary and future directions.Cancer Treat Rep. 1982;66:1045–1055.
- Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.
- Anderson T, Bender RA, Fisher RI et al. Combination chemo- therapy in non-Hodgkin’s lymphoma: results of long-term fol- lowup.Cancer Treat Rep. 1977;61:1057–1066.
- Dana BW, Dahlberg S, Nathwani B, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.J Clin Oncol. 1993;11:644–651.
- Lister TA. The management of follicular lymphoma.Ann Oncol. 1991;2(suppl 2):131–135.
- Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma.J Clin Oncol. 1987;5:407–412.
- Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara-C and dexamethasone (DHAP).Blood. 1988;71:117–122.
- Dana BW, Dahlberg S, Miller TP, et al. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.J Clin Oncol. 1990;8:1155–1162.
- Weick JK, Dahlberg S, Fisher RI et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin’s lymphoma with MACOP-B: a Southwest Oncology Group study.J Clin Oncol. 1991;9:748–753.
- Gams RA, Rainey M, Dandy M, Bartolucci AA., Silberman H, Omura G. Phase III study of BCOP v CHOP in unfavorable cate- gories of malignant lymphoma: a Southeastern Cancer Study Group trial.J Clin Oncol. 1985;3:1188–1195.
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone mar- row transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.N Engl J Med. 1995;333:1540–1545. CrossRef
- Kasakura S. Recent developments in basic and clinical hemato- poietic stem cell transplantation [editorial].Int J Hematol. 2003; 77:1–2. CrossRef
- Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow trans- plantation for B-cell lymphomaN Engl J Med. 1991;25:1525–1533.
- Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999;94:3325–3333.
- Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autol- ogous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial.Lancet. 2002;359:2065–2071. CrossRef
- Kantarjian H, Barlogie B, Plunkett W, et al. High-dose cytosine ara- binoside in non-Hodgkin’s lymphoma.J Clin Oncol. 1983;1: 689–694.
- Velasquez WS, McLaughlin P,Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.J Clin Oncol. 1994;12:1169–1176.
- Ohkubo T, Hori H, Higashigawa M, et al. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.Adv Exp Med Biol. 1989;253B:355–362.
- Chang TT, Gulati SC, Chou TC et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by com- puter analysis.Cancer Res. 1985;45:2434–2439.
- Ogura M, Kagami Y, Suzuki R, et al. Phase I/II trial of cure- oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomag- netic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.Cancer Chemother Pharma- col. 1997;40(suppl):S51-S57. CrossRef
- Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.
- Adelstein DJ, Lazarus HM, Hines JD, Herzig RH. High-dose cyto- sine arabinoside in previously treated patients with poor-prognosis non-Hodgkin’s lymphoma.Cancer. 1985;56:1493–1496. CrossRef
- Freedman A, Gribben J, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.Blood. 1996;88:2780–2786.
- Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemo- therapy.J Clin Oncol. 1999;17:268–276.
- Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxi- city and efficacy in relapsed and refractory non-Hodgkin’s lym- phoma.J Clin Oncol. 1993;11:1573–1582.
- Olivieri A, Offidani M, Ciniero L, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma.Bone Marrow Trans- plant. 1995;16:85–93.
- Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.Blood. 1994;83: 636–640.
- Freedman A, Neuberg D, Mauch P, et al. Cyclophosphamide, dox- orubicin, vincristine, prednisone dose intensification with granulo- cyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.Blood. 1997;90: 4996–5000.
- Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lym- phoma.Br J Haematol. 2000;109:729–735. CrossRef
- Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.Blood. 2000;96:864–869.
- Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma
International Journal of Hematology
Volume 77, Issue 5 , pp 503-511
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- CHASE therapy
- Relapsed lymphoma
- Salvage chemotherapy
- PBSC mobilization
- Industry Sectors